Without IgG2a preadministration | 111In-NLS-7G3 with IgG2a preadministration | F(ab′)2 fragments | ||||
Organ | 111In-NLS-7G3 | 111In-NLS-BM4 | BM4 excess | 7G3 excess | 111In-NLS-7G3 | 111In-NLS-BM4 |
Blood | 0.2 ± 0.1 | 0.2 ± 0.1 | 4.0 ± 1.0* | 7.6 ± 1.7* | 1.4 ± 0.8† | 0.6 ± 0.1 |
Liver | 4.0 ± 2.3 | 2.0 ± 0.1 | 7.3 ± 1.0 | 8.0 ± 0.5 | 3.5 ± 1.9 | 1.3 ± 0.4 |
Spleen | 35.4 ± 13.9 | 31.6 ± 2.4 | 27.0 ± 4.1 | 36.1 ± 3.9 | 5.0 ± 4.6 | 11.0 ± 0.2 |
Kidneys | 6.2 ± 1.7 | 4.9 ± 0.5 | 9.4 ± 1.0 | 12.0 ± 0.6 | 9.6 ± 2.4 | 13.7 ± 4.4 |
Muscle | 1.0 ± 0.9 | 1.0 ± 0.2 | 0.9 ± 0.3 | 1.0 ± 0.2 | 1.0 ± 0.4 | 0.6 ± 0.1 |
Raji-CD123 | 1.4 ± 0.5 | 0.7 ± 0.4 | 14.7 ± 2.8*,‡ | 5.5 ± 3.1* | 7.2 ± 3.8† | 0.3 ± 0.1 |
Raji | ND | ND | 2.1 ± 0.6 | ND | ND | ND |
* Significantly different (P < 0.05), compared with 111In-NLS-7G3 or 111In-NLS-BM4 without preadministration of excess IgG2a.
† Significantly different (P < 0.05), compared with 111In-NLS-7G3 and 111In-NLS-BM4 F(ab′)2.
‡ Significantly different (P < 0.05), compared with nontransfected Raji tumors.
Data are %ID/g (mean ± SD).
ND = Not determined.
Results were obtained at 72 h after injection for intact IgG2a and at 48 h after injection for F(ab′)2 fragments.